AbbVie, OSE Immunotherapeutics Strike Deal to Develop Monoclonal Antibody for Chronic Inflammation

OSE-230 was developed to activate a unique mechanism for resolving chronic inflammation, focusing on modulation of macrophages and neutrophils.

Source link
#AbbVie #OSE #Immunotherapeutics #Strike #Deal #Develop #Monoclonal #Antibody #Chronic #Inflammation